| CAS NO: | 83461-56-7 |
| 包装: | 1mg |
| 市场价: | 5400元 |
Mifamurtide(CGP19835; MTP-PE)可作用于骨肉瘤。
| Cas No. | 83461-56-7 |
| 别名 | 米伐木肽; MTP-PE; L-MTP-PE; CGP 19835 |
| Canonical SMILES | CCCCCCCCCCCCCCCC(OC[C@@H](OC(CCCCCCCCCCCCCCC)=O)COP(OCCNC([C@@H](NC(CC[C@@H](NC([C@@H](NC([C@H](O[C@]([C@H](O)[C@H](O)CO)([H])[C@H](C=O)NC(C)=O)C)=O)C)=O)C(N)=O)=O)C)=O)(O)=O)=O |
| 分子式 | C59H109N6O19P |
| 分子量 | 1237.5 |
| 溶解度 | DMSO: ≥ 100 mg/mL (80.81 mM) |
| 储存条件 | Store at -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | Mifamurtide(CGP19835; MTP-PE) is a drug against osteosarcoma.Target: OthersMifamurtide is an immunomodulator with antitumor effects that appear to be mediated via activation of monocytes and macrophages. Mifamurtide is generally well tolerated; adverse events attributed to administration of the drug include chills, fever, headache, nausea, and myalgias. Based on the available data, mifamurtide can be considered for inclusion in treatment protocols for localized osteosarcoma [1]. Mifamurtide has orphan drug status for the treatment of osteosarcoma in the US and EU [2]. [1]. Frampton, J.E., Mifamurtide: a review of its use in the treatment of osteosarcoma. Paediatr Drugs, 2010. 12(3): p. 141-53. [2]. Mifamurtide: CGP 19835, CGP 19835A, L-MTP-PE, liposomal MTP-PE, MLV 19835A, MTP-PE, muramyltripeptide phosphatidylethanolamine. Drugs R D, 2008. 9(2): p. 131-5. |
m.cnreagent.com